Roche's Anti-IL-33R Astegolimab Fails Late-Stage Trial in COPD

Roche reported on 21 July that its IL-33 receptor blocker astegolimab did not meet the primary endpoint in the Phase III ARNASA trial for chronic obstructive pulmonary disease (COPD), showing a 14.5% reduction in annualised exacerbation rates (AER) versus placebo without statistical significance. This contrasts with the Phase IIb ALIENTO trial, where the same dose (biweekly subcutaneous injection) achieved a statistically significant 15.4% AER reduction.

Astegolimab's safety profile aligned with prior studies, with no new signals observed. The drug, licensed from Amgen in 2016, inhibits IL-33-mediated inflammation. Both trials enrolled 1,300+ COPD patients regardless of smoking status or eosinophil levels. Roche will evaluate next steps for the program amid lower-than-expected exacerbation events across studies.

According to PharmCube's NextBiopharm® database, monoclonal antibody astegolimab uses the most popular drug modality among all 38 IL-33/IL-33R candidates, none of which are approved yet. Click here to request a free trial for NextBiopharm®.

Daily News
MediLink Files B7-H3 ADC as First Phase III-Proven Candidate Globally
2026-07-21
Vincentage Files First Domestic Oral GLP-1 Agonist in China
2026-07-21
BriSTAR's Allogeneic STAR-T Product YTS109 Clears US FDA IND for AIHA
2026-07-20
MSD's Oral PCSK9 Inhibitor Nodded for Hypercholesterolaemia in US
2026-07-20
BI Celebrates Strong H1'26 Growth Driven by Human Pharma Expansion
2026-07-17
Latest Report
2026 TOP-25 Drug Targets
Details